Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Aprocitentan Formulations in Healthy Subjects
NCT05196399Phase 1Completed
- Sponsor
- Idorsia
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aprocitentan in hypertension (HTN) (2 arms), sponsored by Idorsia. Primary endpoints: Maximum plasma concentration at Day 10, Area under the plasma concentration-time curve from zero to time t at Day 10 and 1 more. Started Feb 2022; status: completed.
02
Drugs
aprocitentan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05196399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05196399.